Pentobarbital will minimize the extent or outcome of lumefantrine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with sturdy CYP3A4 inducers can lead to lessened serum concentrations and loss of antimalarial efficacy pentobarbital will decrease the extent or outcome of tamoxifen by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Us... https://bettes234ewn5.wikiannouncement.com/user